BioSpace News Archive

Neuvotion, Inc. is an early-stage medical device company developing neurostimulation products for the rehabilitation, brain-computer interface, and physical therapy markets, announced that it has received an additional $1.25M in funding, bringing cumulative funding to over $2.75M.

Verismo Therapeutics, a clinical-stage CAR T company, University of Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced the presentation of a poster titled, “A Phase 1 KIR-CAR Clinical Trial for Patients with Cholangiocarcinoma, Mesothelioma, or Ovarian Cancers,” at the Annual Cholangiocarcinoma Foundation Conference in Salt Lake City, Utah, April 12-14.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx” or “Company”), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has announced that on April 12, the first patient of the Phase 3 clinical trial (SEER-2) of RGN-259, a novel treatment for neurotrophic keratitis (NK), has been enrolled and begun treatment.

Axsome Therapeutics, Inc. today announced that it will report its financial results for the first quarter of 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets.

atai Life Sciences announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).

biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample.

Aviceda Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for AVD-104, enabling the company to proceed with initiating Phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 20, 2023.

BeiGene, a global biotechnology company, announced the first major step in the company’s expansion in Latin America with the formal opening of its office in São Paulo, Brazil.

Premia Spine today announced the U.S. Food and Drug Administration (FDA) has completed four Bioresearch Monitoring (BIMO) inspections as part of the PMA approval process for the TOPS facet joint replacement system.